As such, inhibitors of DYRK1A/B have been shown to sensitize quiescent cancer cells to imatinib11 and DNA damaging agents such as cisplatin18, 25, 26 and gemcitabine18 through reversal of quiescence and increased cell cycling. Here, DYRK1A is linked to cancer.